Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

HB 126090th Legislature (2027)

Relating to the disclosure of financial interests by and the regulation of advertising by health care practitioners who promote or facilitate the sale of drugs to consumers; providing administrative and civil penalties.

Introduced

Underlined text would be added to current law. Struck-through text would be removed.

 
 
  By: McGee H.B. No. 1260
 
 
  A BILL TO BE ENTITLED
  AN ACT
  relating to the disclosure of financial interests by and the
  regulation of advertising by health care practitioners who promote
  or facilitate the sale of drugs to consumers; providing
  administrative and civil penalties.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  SHORT TITLE. This Act may be cited as the
  Practitioner Drug Promotion Transparency Act.
         SECTION 2.  Subtitle A, Title 3, Occupations Code, is
  amended by adding Chapter 118 to read as follows:
  CHAPTER 118. PROMOTION AND SALE OF DRUGS BY HEALTH CARE
  PRACTITIONERS
         Sec. 118.001.  DEFINITIONS. In this chapter:
               (1)  "Advertising" means any communication made to the
  public or to a consumer, in any medium, that promotes the purchase
  or use of a drug, including a statement made on an Internet website,
  a social media platform, a newsletter, a subscription publication,
  a podcast, a broadcast, a video, a livestream, an e-mail, or a text
  message, and including a link, discount code, or other means of
  directing a consumer to a point of sale.
               (2)  "Affiliated entity" means a person in which a
  health care practitioner or a member of the practitioner's
  immediate family holds a financial interest, including a pharmacy,
  telemedicine platform, distributor, wholesaler, or online
  retailer.
               (3)  "Covered sale" means a sale or dispensing of a drug
  to a consumer in this state in which a health care practitioner has
  a financial interest, whether the drug is dispensed under a
  prescription drug order, under a statewide standing order or
  protocol, or without a prescription.
               (4)  "Drug" has the meaning assigned by Section
  431.002, Health and Safety Code, and includes a compounded drug.
               (5)  "Financial interest" means any direct or indirect
  interest in, or expectation of, remuneration that varies with or is
  contingent on the sale of a drug, including:
                     (A)  an ownership or investment interest in an
  affiliated entity;
                     (B)  a commission, affiliate fee, referral fee,
  royalty, or share of revenue or profit;
                     (C)  compensation attributable to a discount
  code, tracking link, or similar referral mechanism; and
                     (D)  a consulting, speaking, sponsorship, or
  licensing fee paid by a person that manufactures, compounds,
  distributes, or dispenses the drug.
  The term does not include ownership of less than one percent of the
  outstanding securities of a publicly traded company, or a
  reasonable fee for professional services lawfully billed to a
  patient that does not vary with the patient's purchase of a
  particular drug.
               (6)  "Health care practitioner" means an individual
  licensed, certified, or registered under this title who is
  authorized to prescribe or order a drug.
               (7)  "Licensing authority" means the state agency that
  issued the health care practitioner's license, certification, or
  registration.
               (8)  "Unapproved use" means the use of a drug for a
  disease, condition, or purpose that is not included in the drug's
  labeling approved by the United States Food and Drug
  Administration.
         Sec. 118.002.  APPLICABILITY.  This chapter applies to a
  health care practitioner who, directly or through an affiliated
  entity or agent, advertises a drug in which the practitioner has a
  financial interest or facilitates a covered sale, regardless of
  whether the practitioner has a practitioner-patient relationship
  with the consumer.
         Sec. 118.003.  REQUIRED DISCLOSURES IN ADVERTISING AND AT
  POINT OF SALE. (a)  A health care practitioner who advertises a
  drug in which the practitioner has a financial interest shall
  include in the advertising a clear and conspicuous statement that:
               (1)  the practitioner has a financial interest in the
  sale of the drug;
               (2)  describes the nature of the financial interest,
  including whether the practitioner owns or is compensated by the
  seller; and
               (3)  if the advertising promotes an unapproved use,
  states: "This drug has not been approved by the U.S. Food and Drug
  Administration for the use described. Talk to a licensed health
  care provider who does not profit from this sale before taking it."
         (b)  Before a covered sale is completed through an Internet
  website or other remote ordering system, the seller and the health
  care practitioner shall ensure the consumer is shown, on a page the
  consumer must view before payment:
               (1)  the disclosures required by Subsection (a);
               (2)  the name, address, and license number of each
  health care practitioner who has a financial interest in the sale;
               (3)  the name, license number, and physical address of
  the pharmacy or other person that will dispense the drug;
               (4)  a statement that the consumer may obtain the drug,
  if lawfully available, from any pharmacy of the consumer's
  choosing; and
               (5)  the address of an Internet website maintained by
  the licensing authority where the consumer may file a complaint.
         (c)  A statement required by this section is clear and
  conspicuous only if it is:
               (1)  in written advertising, displayed in the body of
  the advertising itself, and not only in a linked page, profile, or
  caption that requires the consumer to expand or click, in a type
  size at least as large as the largest type used to describe the
  drug's benefits;
               (2)  in audio or video advertising, spoken at the
  beginning of the communication and, for video, also displayed on
  screen for not less than five seconds; and
               (3)  in a livestream or recurring broadcast, repeated
  at least once every 15 minutes during which the drug is promoted.
         (d)  The licensing authorities, in consultation with the
  Health Professions Council, may adopt rules prescribing additional
  format requirements for disclosures on specific media platforms.
         Sec. 118.004.  PUBLIC REPORTING OF FINANCIAL INTERESTS. (a)  
  Not later than March 1 of each year, a health care practitioner who
  had a financial interest in a covered sale or who advertised a drug
  in which the practitioner had a financial interest during the
  preceding calendar year shall file a report with the practitioner's
  licensing authority that includes:
               (1)  the name and address of each affiliated entity and
  each person from whom the practitioner received remuneration
  described by Section 118.001(5);
               (2)  each drug advertised or sold, and each disease or
  condition for which the practitioner promoted the drug;
               (3)  the total remuneration received, reported in
  ranges prescribed by rule of the licensing authority; and
               (4)  the approximate number of covered sales.
         (b)  The licensing authority shall make the information
  described by Subsections (a)(1), (2), and (3) available to the
  public on its Internet website, including in any public profile of
  the practitioner maintained by the licensing authority.
         (c)  Information described by Subsection (a)(4) is
  confidential, except that it may be disclosed in a disciplinary
  proceeding or an enforcement action under this chapter.
         Sec. 118.005.  UNSUPPORTED CLAIMS PROHIBITED.  (a)  A health
  care practitioner may not, in advertising for a drug in which the
  practitioner has a financial interest, represent that the drug
  prevents, treats, mitigates, or cures a disease or condition
  unless:
               (1)  that use is included in the drug's labeling
  approved by the United States Food and Drug Administration; or
               (2)  at the time the representation is made, the
  representation is substantiated by competent and reliable
  scientific evidence, which must include at least one adequate and
  well-controlled clinical study in humans, published in a
  peer-reviewed scientific or medical journal, that demonstrates the
  claimed effect for that disease or condition.
         (b)  A representation is not substantiated under Subsection
  (a)(2) if it is based solely on laboratory or in vitro data, animal
  studies, the drug's mechanism of action, anecdotal reports, or the
  practitioner's personal clinical experience.
         (c)  The health care practitioner bears the burden of
  producing the substantiation required by Subsection (a)(2) in a
  disciplinary proceeding or enforcement action under this chapter.
         Sec. 118.006.  NONPRESCRIPTION AND REMOTE SALES. (a)  A
  health care practitioner may not hold a financial interest in, or
  accept remuneration from any person in connection with, the
  dispensing of a drug by a pharmacist under a statewide standing
  order or protocol that authorizes dispensing without a
  patient-specific prescription drug order, including dispensing
  under Chapter 446, Health and Safety Code.
         (b)  A health care practitioner who has a financial interest
  in a covered sale may not issue a prescription drug order for that
  sale unless the practitioner has established a
  practitioner-patient relationship that meets the standard of care,
  as provided by Chapter 111.  A practitioner-patient relationship is
  not established for purposes of this subsection solely by the
  consumer's completion of an online questionnaire or by the
  consumer's purchase of the drug.
         (c)  Before issuing a prescription drug order for a covered
  sale, the health care practitioner shall provide the patient the
  written disclosures required by Section 118.003(b) and obtain the
  patient's acknowledgment, which may be electronic, and shall retain
  the acknowledgment in the patient's medical record.
         Sec. 118.007.  EXCEPTIONS. This chapter does not apply to:
               (1)  a statement, opinion, publication, testimony, or
  other communication by a health care practitioner who does not have
  a financial interest in the sale of the drug that is the subject of
  the communication;
               (2)  a communication made solely to another health care
  practitioner in a professional or scientific context, including a
  peer-reviewed publication or a presentation at a professional
  conference, that does not include a point of sale or referral
  mechanism;
               (3)  a drug sample provided without charge in
  compliance with federal law;
               (4)  the provision or dispensing of a drug by a
  physician in compliance with Chapter 158, other than through
  advertising to the public; or
               (5)  a drug administered to a patient in a hospital,
  ambulatory surgical center, or the practitioner's office as part of
  a course of treatment.
         Sec. 118.008.  ENFORCEMENT; PENALTIES.  (a)  A violation of
  this chapter by a health care practitioner is:
               (1)  unprofessional conduct and a ground for
  disciplinary action by the practitioner's licensing authority
  under the law governing the practitioner's license, including
  Section 164.051 for a physician; and
               (2)  a false, misleading, or deceptive act or practice
  under Section 17.46, Business & Commerce Code, and is actionable
  under Subchapter E, Chapter 17, Business & Commerce Code.
         (b)  A person who violates this chapter is liable to the
  state for a civil penalty of not more than $10,000 for each
  violation. Each advertisement disseminated and each covered sale
  made in violation of this chapter constitutes a separate violation.
         (c)  The maximum civil penalty under Subsection (b) is
  doubled for a violation of Section 118.005 that relates to a disease
  or condition that is the subject of a public health disaster
  declared under Section 81.003, Health and Safety Code, or a state of
  disaster declared under Chapter 418, Government Code, if the
  violation occurs while the declaration is in effect.
         (d)  The attorney general, or the district attorney or county
  attorney of a county in which a consumer who received the
  advertising or purchased the drug resides, may bring an action to
  recover a civil penalty, obtain restitution for affected consumers,
  or obtain injunctive relief under this chapter.  A prosecuting
  attorney who prevails in an action under this subsection may
  recover reasonable attorney's fees and investigative costs.
         (e)  A licensing authority shall refer a complaint alleging a
  violation of this chapter to the attorney general and to the
  appropriate local prosecuting attorney not later than the 30th day
  after the date the licensing authority determines the complaint is
  not frivolous.
         (f)  The remedies provided by this chapter are cumulative of
  any other remedy provided by law.
         Sec. 118.009.  RULES. Each licensing authority shall adopt
  rules as necessary to implement this chapter. The Health
  Professions Council shall coordinate the rules to ensure consistent
  disclosure standards across licensing authorities.
         SECTION 3.  Chapter 446, Health and Safety Code, is amended
  by adding Sections 446.003 and 446.004 to read as follows:
         Sec. 446.003.  REFERRAL PAYMENTS PROHIBITED; DISCLOSURE.  
  (a)  A pharmacist or pharmacy may not pay or offer remuneration of
  any kind to a health care practitioner, as defined by Section
  118.001, Occupations Code, or to any other person in exchange for
  referring, directing, or recruiting a consumer to purchase
  ivermectin dispensed under Section 446.001.
         (b)  A pharmacist who dispenses ivermectin under Section
  446.001 shall provide the consumer a written notice stating:
  "Ivermectin has not been approved by the U.S. Food and Drug
  Administration to prevent or treat COVID-19, hantavirus, or other
  viral infections. Taking more than the recommended dose can cause
  serious harm."
         (c)  A violation of Subsection (a) is grounds for
  disciplinary action by the Texas State Board of Pharmacy and
  constitutes a violation of Chapter 102, Occupations Code.
         Sec. 446.004.  ANNUAL REPORT. Not later than March 1 of each
  year, each pharmacy that dispensed ivermectin under Section 446.001
  during the preceding calendar year shall report to the Texas State
  Board of Pharmacy, in the form prescribed by the board, the number
  of doses dispensed and any adverse event reported to the pharmacy.
  The board shall publish an aggregate summary of the reports on its
  Internet website.
         SECTION 4.  Section 154.006(a), Occupations Code, is amended
  by adding Subdivision (__) to read as follows:
         (__) the information required to be made public under Section
  118.004, as reported by the physician;
         SECTION 5.  Not later than December 1, 2027, each licensing
  authority shall adopt the rules required by Section 118.009,
  Occupations Code, as added by this Act.
         SECTION 6.  (a) Sections 118.003, 118.005, and 118.006,
  Occupations Code, as added by this Act, apply only to advertising
  disseminated or a sale made on or after January 1, 2028.
         (b)  A health care practitioner is not required to file a
  report under Section 118.004, Occupations Code, as added by this
  Act, before March 1, 2029.
         (c)  Section 446.003, Health and Safety Code, as added by
  this Act, applies only to remuneration paid or offered on or after
  January 1, 2028.
         SECTION 7.  SEVERABILITY. If any provision of this Act or
  its application to any person or circumstance is held invalid, the
  invalidity does not affect other provisions or applications of this
  Act that can be given effect without the invalid provision or
  application, and to this end the provisions of this Act are
  severable.
         SECTION 8.  This Act takes effect September 1, 2027.

Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.